Gsk (GSK) Notes Payables (2016 - 2025)
Historic Notes Payables for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$3.9 billion.
- Gsk's Notes Payables fell 170814.07% to -$3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.9 billion, marking a year-over-year decrease of 170814.07%. This contributed to the annual value of -$3.0 billion for FY2024, which is 18581.81% down from last year.
- According to the latest figures from Q3 2025, Gsk's Notes Payables is -$3.9 billion, which was down 170814.07% from -$366.9 million recorded in Q2 2025.
- In the past 5 years, Gsk's Notes Payables registered a high of $4.9 billion during Q4 2021, and its lowest value of -$7.0 billion during Q2 2021.
- Over the past 5 years, Gsk's median Notes Payables value was -$299.4 million (recorded in 2022), while the average stood at -$600.0 million.
- In the last 5 years, Gsk's Notes Payables soared by 9436.96% in 2021 and then tumbled by 322863.29% in 2024.
- Quarter analysis of 5 years shows Gsk's Notes Payables stood at $4.9 billion in 2021, then decreased by 4.51% to $4.6 billion in 2022, then dropped by 24.68% to $3.5 billion in 2023, then crashed by 186.35% to -$3.0 billion in 2024, then fell by 27.79% to -$3.9 billion in 2025.
- Its Notes Payables stands at -$3.9 billion for Q3 2025, versus -$366.9 million for Q2 2025 and -$2.5 billion for Q1 2025.